Company U2Bio Co., Ltd.

Equities

A221800

KR7221800006

Healthcare Facilities & Services

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Company contact information

Sector

Sales per Business

Sales per region

Annual profits - Rate of surprise

Sector Other Healthcare Facilities & Services

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-06-17 pm EDT			5-day change	1st Jan Change
3,900 ^KRW	-1.27%		-8.13%	-26.14%

2023	U2Bio Co., Ltd. has filed an IPO.	CI
2020	Chang Moo Jeon acquired 8.5% stake in U2Bio CO. LTD. from MAC Fund, L.P. (Class B), a fund managed by M-Venture Investment, Inc. for KRW 1.6 billion.	CI

U2BIO CO., LTD. is a Korea-based company mainly engaged in the provision of diagnostic testing services. The Company is involved in the provision of the general diagnostic testing services, molecular diagnostic testing services, as well as medical information technology (IT) services. The general diagnostic testing services include the provision of diagnosis and inspection information such as immunological serology, hematology, urine and microbiology, and pathology excluding molecular diagnostics among in vitro diagnostic tests. The Molecular diagnostic testing services include the provision of diagnostic and testing information through tests such as urethritis, mastoiditis, vaginitis, and cervicitis. The medical IT services include the provision of customized medical services through software products.

KRW in Million	2022	Weight	2023	Weight	Delta
General Diagnostic Check Service 35.2 %	11,069	16.0 %	10,830	35.2 %	-2.16%
General Diagnostic Test Reagents, Etc. 23.3 %	-	-	7,175	23.3 %	-
Molecular Diagnostic Examination Service 14.4 %	24,954	36.2 %	4,437	14.4 %	-82.22%
Others 14.0 %	1,738	2.5 %	4,298	14.0 %	+147.30%
Molecular Diagnostic Test Reagents, Etc. 7.3 %	-	-	2,236	7.3 %	-
Medical Information Technology Solutions Service 5.7 %	1,689	2.4 %	1,762	5.7 %	+4.32%
Medical Information Technology Solutions Merchandise 0.2 %	-	-	55	0.2 %	-

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 99.2 %	68,806	99.7 %	30,559	99.2 %	-55.59%
Overseas 0.8 %	208	0.3 %	233	0.8 %	+12.42%

Managers	Title	Age	Since
Jin-Tae Kim CEO	Chief Executive Officer	60	09-10-31
Ji-Won Kim CTO	Chief Tech/Sci/R&D Officer	53	10-12-31
Hyuk-Sung Jin BRD	Director/Board Member	52	-
Jang-Ho Park BRD	Director/Board Member	53	-
Hyun-Seok Kim AUD	Comptroller/Controller/Auditor	51	-

Members of the board	Title	Age	Since
Jang-Ho Park BRD	Director/Board Member	53	-
Jin-Tae Kim CEO	Chief Executive Officer	60	09-10-31
Ji-Won Kim CTO	Chief Tech/Sci/R&D Officer	53	10-12-31
Hyuk-Sung Jin BRD	Director/Board Member	52	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	11,287,196	5,063,403 ( 44.86 %)	0	44.86 %

U2Bio Co., Ltd.

Geuk Il Building 65 Geoma-ro

05734, Seoul

http://www.u2bio.co.kr

Company calendar

Healthcare

Healthcare Services

Healthcare Providers & Services

Healthcare Facilities & Services

Other Healthcare Facilities & Services

	1st Jan change	Capi.
U2BIO CO., LTD.	-26.14%	32.28M
HCA HEALTHCARE, INC.	+25.85%	87.86B
CVS HEALTH CORPORATION	-22.73%	76.69B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+3.24%	26.86B
FRESENIUS SE & CO. KGAA	+2.00%	17.76B
QUEST DIAGNOSTICS INCORPORATED	-0.42%	15.22B
NATERA, INC.	+72.40%	13.56B
TENET HEALTHCARE CORPORATION	+81.96%	13.37B
PURE HEALTH HOLDING	-24.56%	13.01B
UNIVERSAL HEALTH SERVICES, INC.	+25.01%	12.7B

Other Healthcare Facilities & Services